Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial | BMC Cancer | Full Text

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial | BMC Cancer | Full Text

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mC...

Authors:Charlien Berghen, Steven Joniau, Kato Rans, Gaëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans and Gert De Meerleer

Citation:BMC Cancer 2020 20:457

Content type:Study protocol

Published on: 24 May 2020

• ViewFull Text
 
• ViewPDF